; (ii) if the drug is included on the drug shortage list under section 506E of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356e ). (C) Establishment of procedures to avoid duplication The Secretary shall establish procedures to ensure that there is no duplication with respect to drug rebates provided by manufacturers with respect to applicable part B drugs under this subsection and either of the following: (i) Purchase by a covered entity of covered outpatient drugs pursuant to an agreement under section 340B of the Public Health Service Act ( 42 U.S.C. 256b ). (ii) Drug rebates provided by manufacturers with respect to covered outpatient drugs pursuant to section 1927. (2) Rebate agreement A rebate agreement under this subsection shall require the manufacturer to provide to the Secretary (to be deposited in the Treasury to the credit of the Federal Supplementary Medical Insurance Trust Fund) a rebate for each rebate period (as defined in paragraph (7)(B)) ending after December 31, 2019, in an amount specified in paragraph (4) for applicable part B drugs of the manufacturer furnished after December 31, 2019, for which payment was made under this section or under a separate ambulatory classification group pursuant to section 1833(t) for such period. Such rebate shall be paid by the manufacturer not later than 30 days after the date of receipt of the information described in paragraph (3) for the period involved. (3) Secretary provision of information (A) In general The Secretary shall report to each manufacturer not later than 180 days after the end of each rebate period and in a form consistent with a standard reporting format established by the Secretary, information on the total number of units of each dosage form and strength and package size of each applicable part B drug of the manufacturer furnished after December 31, 2019, for which payment was made under this section or under a separate ambulatory classification group pursuant to section 1833(t) during the period. (B) Audits by manufacturer of